George Rajan Simon Selected Research

3- (4- bromo- 2,6- difluorobenzyloxy)- 5- (3- (4- pyrrolidin- 1- ylbutyl)ureido)isothiazole- 4- carboxylic acid amide

6/2007

A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

George Rajan Simon Research Topics

Disease

1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2007
1	Diarrhea 06/2007
1	Exanthema (Rash) 06/2007

Drug/Important Bio-Agent (IBA)

1	3- (4- bromo- 2,6- difluorobenzyloxy)- 5- (3- (4- pyrrolidin- 1- ylbutyl)ureido)isothiazole- 4- carboxylic acid amideIBA 06/2007
1	Carboplatin (JM8)FDA LinkGeneric 06/2007
1	Paclitaxel (Taxol)FDA LinkGeneric 06/2007

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 06/2007